International Journal of Clinical Pharmacy

, Volume 40, Issue 4, pp 769–774 | Cite as

Overview of pharmacovigilance practices at the largest academic healthcare system in the State of Qatar

  • Moza Al Hail
  • Wessam Elkassem
  • Anas Hamad
  • Pallivalappila Abdulrouf
  • Binny ThomasEmail author
  • Derek Stewart


Adverse Drug Reactions (ADRs) are major global concern, adversely impacting patient safety and health outcomes. ADRs cause significant morbidity and mortality among hospitalised patients, causing greater length of hospital stay, increased healthcare costs and patient dissatisfaction to the treatments. Pharmacovigilance (PV), a process of detecting, monitoring and preventing drug-related harm, plays a vital role to ensure patient safety. ADR reporting is the cornerstone of PV. PV practices in Qatar are relatively new and are evolving rapidly. The purpose of this article is to explore the medication safety practices (notably ADR reporting) at the largest academic healthcare center in Qatar. The article further provides evidence on how information related to ADRs are generated and interpreted. Furthermore, it describes how a designated center for monitoring medication safety activities was established at the largest healthcare provider in Qatar.


Adverse Drug Reactions Hamad Medical Corporation Medication safety Pharmacovigilance Qatar 



No funding was received for this paper.

Conflicts of interest

All the authors declare that they have no conflict of interest.


  1. 1.
    World Health Organization. Reporting and learning systems for medication errors: the role of pharmacovigilance centers. 2014. Accessed 05 Feb 2018.
  2. 2.
    World Health Organization. International drug monitoring: the role of the hospital, report of a WHO meeting [held in Geneva from 18 to 23 November 1968]. 1969. Accessed 05 Feb 2018.
  3. 3.
    Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA. 2005;294(10):1255–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Wester K, Jönsson AK, Spigset O, Druid H, Hägg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol. 2008;65(4):573–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE. 2009;4(2):e4439.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Zopf Y, Rabe C, Neubert A, Hahn EG, Dormann H. Risk factors associated with adverse drug reactions following hospital admission. Drug Saf. 2008;31(9):789–98.CrossRefPubMedGoogle Scholar
  7. 7.
    Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI. Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol. 2008;65(3):396–406.CrossRefPubMedGoogle Scholar
  8. 8.
    Khan LM, Al-Harthi S, Saadah OI. Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of pharmacovigilance in reporting ADR. Saudi Pharm J. 2013;21(3):261–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Sridhar SB, Al-Thamer SSF, Jabbar R. Monitoring of adverse drug reactions in psychiatry outpatient department of a Secondary Care Hospital of Ras Al Khaimah, UAE. J Basic Clin Pharm. 2016;7(3):80.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Ministry of Development Planning and Statistics. Total population within the State of Qatar. 2017. Accessed 10 Jan 2018.
  12. 12.
    Ministry of Public Health (MoPH) Qatar. Health objectives: ministry of public health. 2017. Accessed 10 Jan 2018.
  13. 13.
    Ministry of Public Health, Qatar. Health services. 2018. Accessed 22 Jan 2018.
  14. 14.
    National Health Strategy 2011–2016. Healthcare products regulation. General secretariat, supreme council of health. 2014. Accessed 10 Jan 2018.
  15. 15.
    Joint Commission International (JCI). JCI-accredited organizations. 2017. Accessed 19 Dec 2017.
  16. 16.
    The Institute for Healthcare Improvement. Current collaborations in the region—Qatar-Hamad Medical Corporation. Institute for healthcare improvement. 2018. Accessed 10 Jan 2018.
  17. 17.
    International Medication Safety Network (IMSN). Medication safety and quality center (MSQC): Qatar. 2018. Accessed 10 Jan 2018.
  18. 18.
    WHO Program for International Drug Monitoring. Associate members: Qatar. 2018. Accessed 10 Jan 2018.
  19. 19.
    Steurbaut S, Hanssens Y. Pharmacovigilance: empowering healthcare professionals and patients. Int J Clin Pharm. 2014;36(5):859–62.CrossRefPubMedGoogle Scholar
  20. 20.
    ElKassem W, Al Hail M, Rouf A, Hamad A, Thomas B. An evaluation of knowledge, attitude and practice of pharmacists towards adverse drug reactions: a questionnaire based study at Hamad Medical Corporation, Qatar. 2017. Accessed 10 Jan 2018.
  21. 21.
    Almandil NB. Healthcare professionals’ awareness and knowledge of adverse drug reactions and pharmacovigilance. Saudi Med J. 2016;37(12):1359–64.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Alshammari TM, Alamri KK, Ghawa YA, Alohali NF, Abualkol SA, Aljadhey HS. Knowledge and attitude of health-care professionals in hospitals towards pharmacovigilance in Saudi Arabia. Int J Clin Pharm. 2015;37(6):1104–10.CrossRefPubMedGoogle Scholar
  23. 23.
    Hajebi G, Mortazavi SA, Salamzadeh J, Zian A. A survey of knowledge, attitude and practice of nurses towards pharmacovigilance in Taleqani Hospital. Iran J Pharm Res (IJPR). 2010;9(2):199–206.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Hamad Medical CorporationDohaQatar
  2. 2.Robert Gordon UniversityAberdeenUK

Personalised recommendations